Literature DB >> 11918711

Infection with influenza a virus leads to flu antigen-induced cutaneous anaphylaxis in mice.

Susanne M Grunewald1, Christian Hahn, Gisela Wohlleben, Martin Teufel, Tamas Major, Heidrun Moll, Eva-B Bröcker, Klaus J Erb.   

Abstract

It is well established, that viral infections may trigger urticaria or allergic asthma; however, as viral infections induce T helper 1 polarized responses, which lead to the inhibition of T helper 2 cell development, the opposite would be plausible. We wanted to investigate how viral infections may mediate allergic symptoms in a mouse model; therefore, we infected BALB/C mice with influenza A virus intranasally. Histologic analyses of lung sections and bronchoalveolar lavages were performed. In addition, cells from the mediastinal lymph nodes were restimulated in vitro to analyze which types of cytokines were induced by the flu infection. Furthermore, flu-specific antibody titers were determined and local anaphylaxis was measured after rechallenge with flu antigen. We found that airways inflammation consisted predominately of macrophages and lymphocytes, whereas only a few eosinophils were observed. interferon-gamma but no interleukin-4 and little interleukin-5 could be detected in the culture supernatants from in vitro restimulated T cells from the draining lymph nodes. The antibody response was characterized by high levels of virus-specific IgG2a, IgG2b, and IgG1 and, surprisingly, low levels of virus-specific IgE antibodies. Interestingly, flu-infected mice developed active and passive cutaneous anaphylaxis after rechallenge with flu-antigen. As the passive cutaneous anaphylaxis reaction persisted over 48 h and was significantly lower after passive transfer of the serum, which was IgE depleted, local anaphylaxis seemed to be mediated predominately by specific IgE antibodies. Taken together, our results demonstrate that mice infected with flu virus develop virus-specific mast cell degranulation in the skin. Our results may also have implications for the pathogenesis of urticaria or other atopic disorders in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918711     DOI: 10.1046/j.1523-1747.2002.01732.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Intracellular RNA recognition pathway activates strong anti-viral response in human mast cells.

Authors:  J Lappalainen; J Rintahaka; P T Kovanen; S Matikainen; K K Eklund
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

3.  Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine.

Authors:  Tamar A Smith-Norowitz; Darrin Wong; Melanie Kusonruksa; Kevin B Norowitz; Rauno Joks; Helen G Durkin; Martin H Bluth
Journal:  Int J Med Sci       Date:  2011-03-18       Impact factor: 3.738

4.  Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.

Authors:  Gabriel Kristian Pedersen; Thomas Ebensen; Ingrid Hjetland Gjeraker; Signe Svindland; Geir Bredholt; Carlos Alberto Guzmán; Rebecca Jane Cox
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

5.  Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling.

Authors:  Amy C Graham; Kimberly M Hilmer; Julianne M Zickovich; Joshua J Obar
Journal:  J Immunol       Date:  2013-03-22       Impact factor: 5.422

Review 6.  Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection.

Authors:  Ashleigh R Murphy-Schafer; Silke Paust
Journal:  Front Cell Infect Microbiol       Date:  2021-02-19       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.